Azra AI vs RhythmX AI (2026)
Both read what is already in the record to make sure someone acts on it, and they enter at different points. Azra reads pathology and radiology reports the moment they arrive and converts findings into assigned work, so a new cancer diagnosis becomes a navigator's task rather than a document nobody opened, with one of the deepest live integration footprints in this index. RhythmX unites data across sources into a precision care platform aimed at primary care physicians, working the panel rather than a service line. For a cancer programme losing patients between diagnosis and navigation, Azra is pointed at exactly that. For an organisation whose gaps are spread across primary care, RhythmX reaches earlier. Azra publishes almost nothing on privacy or security while consuming live clinical feeds, which is the diligence to do before the integration, not after.
- It reads pathology and radiology reports as they land and turns findings into assigned work, so a newly diagnosed patient becomes someone's responsibility rather than a line in a report.
- The live integration footprint is among the deepest in this index, consuming interface feeds directly rather than querying after the fact.
- For a cancer service line, the failure it addresses is patients falling through the gap between diagnosis and navigation, which is a documented and expensive problem.
- It unites data across sources into a precision care platform aimed at the primary care physician rather than at a service line.
- Primary care is where most missed follow up originates, so acting there reaches patients before a specialist is involved at all.
- The breadth suits an organisation trying to lift care gaps across a panel rather than to route one disease pathway.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Azra AI and RhythmX AI are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Azra AI | RhythmX AI |
|---|---|---|
| Primary category | Healthcare Administrative Automation | Clinical Decision Support |
| Founded | 2022 | 2023 |
| Headquarters | Nashville, Tennessee, United States | Palo Alto, CA, US |
| Website | azra-ai.com | rhythmx.ai |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Azra AI its top capability grade on EHR and Interoperability Depth. Set against RhythmX AI, Azra AI grades higher on Autonomy and Oversight Model, Model Supply Chain Disclosure and EHR and Interoperability Depth. Its thinnest published disclosure sits on several axes, including HIPAA and BAA Posture, Security Certifications and Trust Center and AI Governance and Bias Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards RhythmX AI its top capability grade on AI Centrality. Set against Azra AI, RhythmX AI grades higher on several axes, including AI Centrality, Clinical and Operational Evidence and HIPAA and BAA Posture. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Azra AI or RhythmX AI?
On the axes where the AI Health Index separates them, Azra AI grades higher on Autonomy and Oversight Model, Model Supply Chain Disclosure and EHR and Interoperability Depth, and RhythmX AI grades higher on several axes, including AI Centrality, Clinical and Operational Evidence and HIPAA and BAA Posture. RhythmX AI leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Azra AI and RhythmX AI differ most?
The widest separation the AI Health Index records between Azra AI and RhythmX AI is on Autonomy and Oversight Model, where Azra AI grades B and RhythmX AI grades C. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Azra AI and RhythmX AI grade the same?
The AI Health Index grades Azra AI and RhythmX AI the same on several axes, including Model and Technology Transparency, AI Safety and PHI Stewardship and FDA and Regulatory Status. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Azra AI and RhythmX AI not disclosed?
At the last review, at least one of Azra AI and RhythmX AI published thin or absent detail on several axes, including Model Supply Chain Disclosure, HIPAA and BAA Posture and Security Certifications and Trust Center. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Summarization & Chart Review page.
Azra publishes no health privacy statement, business associate terms, security attestation, retention position or secondary use policy across repeated searches, which is a wide gap for a platform consuming live pathology and radiology feeds across a health system.
Neither vendor publishes a subgroup performance analysis, and for models reading free text reports the predictable failure is systematic: reports written in unusual formats or by particular services are read less reliably, and the patients behind those reports are missed without any signal. Neither publishes pricing. Ask both what proportion of surfaced cases turn out to be actionable.